Business Wire

Pierre Fabre Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Selective Potassium Channel Blocker for Atrial Fibrillation

Del

Pierre Fabre Pharmaceuticals (Pierre Fabre) and Boston Pharmaceuticals Inc. (Boston Pharmaceuticals) today announced they have entered into a worldwide licensing agreement for Pierre Fabre’s selective potassium channel blocker, F17727.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180104005695/en/

F17727 is a small molecule in late preclinical development for the potential treatment of atrial fibrillation (AF). Under the terms of the agreement, Pierre Fabre grants Boston Pharmaceuticals worldwide exclusive rights for the development, manufacturing and commercialization of F17727. Financial terms of the agreement were not disclosed.

While our R&D and commercial focus has shifted away from cardiology, we are committed to ensuring that promising compounds are advanced through strategic partnerships to the benefit of patients,” said Frédéric Duchesne, President & CEO, Pierre Fabre Pharmaceuticals. “Boston Pharmaceuticals’ R&D excellence, collaborative approach and dedication to patients aligns well with our mission and we are pleased to enter this agreement with them for F17727.”

This agreement, with such a patient-driven and innovative partner as Pierre Fabre, marks a further significant step in our plan to assemble a diverse portfolio of clinical candidates across a broad range of mechanisms and therapeutic targets. F17727 represents the seventh addition to our rapidly advancing pipeline and our first candidate that addresses cardiovascular disease,” said Robert Armstrong, Chief Executive Officer of Boston Pharmaceuticals. “We believe F17727 works through a potentially differentiated, highly selective mechanism with the potential to treat atrial fibrillation and look forward to advancing this candidate to further evaluate its potential.”

For more information, please visit www.pierre-fabre.com

For more information, please visit www.bostonpharmaceuticals.com.

Contact information

Pierre Fabre
Valérie Roucoules, (33) 1 49 10 83 84
valerie.roucoules@pierre-fabre.com
or
Boston Pharmaceuticals
Kari Watson, (781) 235 3060
MacDougall Biomedical Communications
kwatson@macbiocom.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cryptos Fund, a Quasi-ETF, Is Now Open to Investors23.1.2018 09:00Pressemelding

Cryptos Fund allows investors to gain exposure to Cryptocurrencies with reduced risk in a regulated environment. Cryptos Fund is the brainchild of a team of leading academics, quants and security experts based in Zug, Switzerland. It is designed to passively track the CCI30 index (www.cci30.com), an indicator of cryptocurrencies valuations and the benchmark for the sector. Carlo Scevola, one of the fund’s principals, says: “Cryptos Fund was initially created as a private investment vehicle. I first bought Bitcoin in 2011, and when its value became substantial I wanted to diversify into other cryptocurrencies with a rigorous scientific approach. There was no suitable option available, so I created my own fund.” Cryptos Fund is also a response to heavy investor demand: “It bridges the gap between the traditional financial system and the cryptocurrencies sector. Investors need to participate in the cryptocurrency market via a regulated entity, which didn’t exist until now.” Cryptos Fund i

HYCM Launches Ripple and Bitcoin Cash Cryptocurrency CFDs23.1.2018 08:48Pressemelding

HYCM, a multi-regulated global leader in online capital markets trading, has launched trading on two additional cryptocurrencies, Ripple and Bitcoin Cash, adding XRP/USD and BCH/USD to its range of cryptocurrency offerings. The decision to add Ripple and Bitcoin Cash to its existing crypto offerings, Bitcoin, Litecoin and Ethereum, follows the continued increase in demand from investors in the wake of the recent cryptocurrency boom. HYCM thus now offers 24/5 leveraged trading on the most volatile virtual currencies coupled with low spreads and competitive margins. Ripple (XRP) is both a transaction network and crypto token which was created in 2012 as the go-to cryptocurrency for banks and global money transfers, and has recently experienced a period of growth. Bitcoin Cash (BCH) meanwhile, is a blockchain derived from the Bitcoin blockchain which followed the split of Bitcoin (hard fork) in August 2017. Bitcoin Cash has also recently experienced gains as investors seek to diversify th

ADOIT 8.3 Unboxed: BOC Group Releases the Next Version of Its Professional EA Suite23.1.2018 08:00Pressemelding

BOC Group is happy to present the next release of ADOIT. Powerful workflow capabilities to manage ever-changing Enterprise Architectures are one, yet not the only, highlight of ADOIT 8.3. BOC Group, an internationally leading vendor and manufacturer of software tools for globally recognized management approaches introduces the next evolution of its powerful 100% web-based EA suite. ADOIT steps out of the box and delivers valuable insights that are easily digested by decision makers through its powerful aggregated views. The EA suite enables to quickly launch Enterprise Architecture and IT Management initiatives and start turning buried or hidden information into business value with easy analysis, just a few clicks away. In the course of delivering more than 1,000 implementation projects worldwide, BOC Group has acquired extensive experience that has benefited ADOIT's development significantly. With the new workflow capabilities and release state filter options in ADOIT 8.3, on top of o

21st Century Fox Welcomes the CMA’s Provisional Finding on Company’s Genuine Commitment to Broadcasting Standards23.1.2018 07:29Pressemelding

21st Century Fox notes today’s publication by the Competition and Markets Authority (CMA) of its Provisional Findings Report regarding the Company’s proposed acquisition of the remaining shares in Sky. Today’s provisional findings move our proposed Sky transaction forward to the next phase of the regulatory review process. We welcome the CMA’s provisional finding that the Company has a genuine commitment to broadcasting standards and the transaction would not be against the public interest in this respect. Regarding plurality, we are disappointed by the CMA’s provisional findings. We will continue to engage with the CMA ahead of the publication of the final report in May. We also note that the CMA has elected to avail itself of the statutory 8-week extension, moving its deadline for a final decision to May 1, 2018. We anticipate regulatory approval of the transaction by June 30, 2018. About 21st Century Fox 21st Century Fox is one of the world's leading portfolios of cable, broadcast,

IDEMIA Announces Acquisition of Otono Networks and Its eSIM Orchestration Solution23.1.2018 06:30Pressemelding

IDEMIA, the global leader in Augmented Identity for an increasingly digital world, today announced the acquisition of Otono Networks and its industry-leading eSIM orchestration technology. Together, IDEMIA and Otono will offer a comprehensive eSIM lifecycle management solution to simplify the adoption of eSIM for both mobile operators (MNOs) and device manufacturers (OEMs). This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006566/en/ This acquisition marks the first external expansion by the IDEMIA group, formed in 2017 when OT (Oberthur Technologies) and Safran Identity & Security (Morpho) joined forces, and illustrates IDEMIA’s strategic vision facing the future of connected devices. By 2020, connected objects in use worldwide could reach 20.4 billion (source: www.gartner.com). Faced with the increasing number of new eSIM devices (smartphones, smartwatches, tablets, PCs, etc.) and IoT applications, MNOs and OEMs must con

Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year23.1.2018 06:30Pressemelding

Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights as one of the 2018 Global 100 Most Sustainable Corporations in the World (Global 100) for the third consecutive year. This distinction is based on 17 key performance indicators including financial management, clean revenue, and supplier performance. Takeda performed in the top 25% on innovation capacity, receiving notable recognition for its leadership diversity. Global 100 companies in 2018 represent the top 1.3% in the world on sustainability performance. The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos. As a LEAD company within the United Nations Global Compact, Takeda’s established track record in sustainability is guided by long-term international targets such as the Sustainable Development Goals (SDGs). Takeda is the only Japanese pharmaceutical company and among the four companies from Japan to make the final 100 in 2018, and one

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom